Key Points {#FPar1}
==========

People with type 2 diabetes (T2D) and healthcare professionals can be reluctant to start insulin therapy.IDegLira is a medicine that combines insulin with a glucagon-like peptide-1 receptor agonist, that can help people with T2D improve their blood sugar and reduce their risk of weight gain and hypoglycemia.IDegLira allows for simple dose adjustment with a once daily injection, which combined with clinical benefits, may make it a more attractive option for those reluctant to start insulin.

Introduction {#Sec1}
============

Type 2 diabetes (T2D) is a chronic, progressive disease with an etiology involving insulin resistance and progressive decline in β-cell function \[[@CR1]\]. Current clinical practice guidelines recommend exercise and diet modification as the first-line therapy, alone or in combination with metformin. Treatment is intensified over time with the addition of further oral antidiabetes drugs (OADs) and/or injectable therapies, often in combination with each other \[[@CR2], [@CR3]\].

Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) mimic naturally occurring GLP-1, a hormone secreted in response to food ingestion that enhances the release of endogenous insulin and suppresses endogenous glucagon secretion, both in a glucose-dependent manner. Both GLP-1RA and basal insulin are recommended treatment options at many stages of T2D. These agents have complementary mechanisms of action, which, when used together, can offer several benefits to people with T2D \[[@CR4], [@CR5]\]. Basal insulin is effective at lowering glycated hemoglobin (HbA~1c~) and fasting plasma glucose (FPG) levels, but increases the risk of hypoglycemia and body weight gain \[[@CR4], [@CR5]\]. Short-acting GLP-1RAs (exenatide, lixisenatide) lower postprandial glucose (PPG) when taken before a meal, whereas long-acting GLP-1RAs (dulaglutide, exenatide extended release, liraglutide, and semaglutide) lower both FPG and PPG; both act in a glucose-dependent manner. GLP-1RAs slow gastric emptying and increase satiety; however, GLP-1RAs can cause gastrointestinal (GI) adverse events, notably nausea and vomiting, especially in the early weeks of therapy. GLP-1RAs are suitable adjuncts to basal insulin as they can mitigate body weight gain and lower the risk of hypoglycemia since their co-use reduces the insulin dose requirement \[[@CR4], [@CR5]\]. Therefore, the combination of these two therapies can be more effective yet better tolerated than basal insulin or GLP-1RA alone.

Co-formulations of oral therapies are well established, with many combinations of different drug classes currently available \[[@CR6]\]. More recently, two injectable fixed-ratio combination (FRC) formulations of basal insulin and GLP-1RA have been approved \[[@CR7]\]: IDegLira (first approved in the EU in 2014, and in the US in 2016) is a once-daily FRC of insulin degludec U100 (degludec) and the GLP-1RA liraglutide \[[@CR8]\]; and IGlarLixi (approved in the US in 2016, and in the EU in 2017) is a once-daily FRC of insulin glargine U100 (IGlar U100) and lixisenatide (a GLP-1RA). Both IDegLira and IGlarLixi demonstrated either non-inferiority or superiority in HbA~1c~ reduction compared with their basal insulin and GLP-1RA components in monotherapy, respectively, in the DUAL I \[[@CR8], [@CR9]\] and LixiLan-O \[[@CR10]\] trials.

The combination of an insulin and a GLP-1RA into one treatment simplifies therapy, halving the number of injections when compared with taking each component separately, and thereby reducing treatment burden \[[@CR11]\]. Additionally, fewer GI adverse events are associated with FRCs of GLP-1RAs compared with the use of GLP-1RAs in free combination, as a result of a lower GLP-1RA starting dose and more gradual titration of the FRC, determined by the insulin component \[[@CR12]\]. Furthermore, oral combination therapies have been shown to significantly improve treatment initiation and persistence compared with usual care \[[@CR13]\]; this may also be applicable to injectable combination therapies. To support their use in clinical practice, clinicians need to be familiar with the initiation and titration of FRC products, and to identify suitable people who will benefit from this therapy \[[@CR14]\].

This review focuses on the clinical evidence for one of the injectable FRCs, namely IDegLira, to explore its potential role in T2D therapy.

Unmet Clinical Need {#Sec2}
===================

Reaching and maintaining personalized glycemic targets has been shown to improve outcomes in people with diabetes by reducing micro- and macrovascular complications \[[@CR15]\]. However, it is well established in clinical practice that people with diabetes often do not reach HbA~1c~ targets \[[@CR16], [@CR17]\] and that healthcare professionals (HCPs) can be reluctant to intensify therapy in a timely manner as recommended by clinical practice guidelines \[[@CR3], [@CR18], [@CR19]\]. This phenomenon has been referred to as therapeutic inertia \[[@CR20]\].

Therapeutic inertia, also called clinical inertia, can lead to delays in initiating insulin therapy in people with T2D with elevated HbA~1c~ levels \[[@CR21]--[@CR23]\]. Although significant improvements in glycemic control have been observed when insulin therapy was initiated in individuals not achieving HbA~1c~ targets with OADs alone, most people still did not achieve an HbA~1c~ target of \< 7.0% (\< 53 mmol/mol), even if this was their target level \[[@CR22]--[@CR24]\].

A number of reasons have been proposed for therapeutic inertia, such as HCPs being concerned about the impact of burdensome regimens on the quality of life of people with T2D, or their fears of causing people with T2D to experience hypoglycemia and body weight gain. It is important to recognize that therapeutic inertia might be the result of shared decision making, as people with diabetes are likely to share these concerns and may be reluctant to intensify their treatment \[[@CR20]\].

A simple, less burdensome injectable therapy with a lower risk of body weight gain and hypoglycemia compared with an insulin-only regimen, requiring only a single daily injection, has the potential to reduce such concerns on the part of both HCPs and people with diabetes, thereby optimizing the ability to achieve relevant HbA~1c~ targets. Furthermore, by combining drugs with complementary actions, an FRC has the potential to provide more durable glycemic control. A durable therapy is defined as one that helps people with diabetes maintain glycemic control for longer and therefore require fewer intensification interventions compared with other treatment options. As a result of the chronic nature of T2D, a durable therapy could play an important role in preventing therapeutic inertia and minimizing chronic exposure to hyperglycemia. Additionally, the need for fewer interventions may lead to people with T2D feeling more positive about their disease management \[[@CR25]\].

Pharmacokinetic and Pharmacodynamic Properties of IDegLira and Its Constituents {#Sec3}
===============================================================================

A one-unit dose (used in the US prescribing information) or dose step (used in the European Summary of Product Characteristics) of IDegLira comprises 1 unit of degludec and 0.036 mg of liraglutide. IDegLira is administered once-daily by subcutaneous injection, at any time of the day, but preferably at the same time each day \[[@CR7]\].

Pharmacokinetic and Pharmacodynamic Properties of Degludec {#Sec4}
----------------------------------------------------------

Degludec is a long-acting, once-daily basal insulin. When injected, degludec forms a subcutaneous depot of multi-hexamers, from which monomers slowly and continuously dissociate \[[@CR26]\]. It has a half-life of more than 25 h (compared with approximately 12 h for IGlar U100 and 5*--*7 h for insulin detemir), and provides a consistent and stable blood glucose-lowering profile over each 24-h dosing interval \[[@CR26]--[@CR28]\], as well as relatively low day-to-day variability in the pharmacodynamic profile compared with other basal insulins \[[@CR29], [@CR30]\]. The within-day variability in the glucose-lowering effect of degludec has also been found to be lower by 40% and 37% compared with IGlar U100 and U300, respectively \[[@CR30]\]. This reduction in glucose-lowering variability is likely to be associated with the significantly lower risk of overall hypoglycemia compared with IGlar U100, as demonstrated in the SWITCH \[[@CR31], [@CR32]\], DEVOTE \[[@CR33]\], and BEGIN \[[@CR34]\] trials. By contrast, morning administration of IGlar U300 0.4 units/kg/day in individuals with type 1 diabetes (T1D) provides less fluctuating 24-h pharmacodynamics and more even pharmacokinetic profiles compared with degludec 100 units/mL \[[@CR35]\].

Pharmacokinetic and Pharmacodynamic Properties of Liraglutide {#Sec5}
-------------------------------------------------------------

Liraglutide is a once-daily, injectable GLP-1RA, sharing 97% sequence homology with human GLP-1 \[[@CR36]\]. It is metabolized by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase at a much slower rate than naturally occurring GLP-1 \[[@CR37]\]. Absorption of liraglutide is slow (reaching maximum concentration 8--12 h after dosing) and the half-life is 13 h, hence its suitability for once-daily dosing \[[@CR36]\]. Liraglutide restores the β-cell insulin response, which is impaired in people with T2D, to levels similar to healthy individuals \[[@CR38]\].

Pharmacokinetic and Pharmacodynamic Properties of IDegLira {#Sec6}
----------------------------------------------------------

The discrete pharmacokinetic properties of degludec and liraglutide are preserved when administered as the IDegLira co-formulation, with equivalence being demonstrated compared with both degludec and liraglutide monotherapy \[[@CR39]\].

The maximum daily dose of IDegLira is 50 units/dose steps \[[@CR7]\], as this delivers the maximum licenced liraglutide dose for diabetes of 1.8 mg \[[@CR36]\]. While there may be concern that the dose of degludec is capped at 50 units in IDegLira, the insulin requirement of people with T2D treated with IDegLira is greatly reduced as a result of the insulin-sparing effect of liraglutide \[[@CR40], [@CR41]\].

Degludec and Liraglutide Clinical Trials {#Sec7}
========================================

Degludec Clinical Trials {#Sec8}
------------------------

BEGIN^®^ was a phase III clinical trial program that investigated the efficacy and safety of degludec in more than 3000 people with T1D or T2D. It demonstrated degludec to be associated with a lower risk of hypoglycemia than IGlar U100 at the same HbA~1c~ level, and to offer more dosing flexibility \[[@CR42]--[@CR46]\]. Both insulin-naïve people \[[@CR43]--[@CR46]\] and those who had previously been treated with insulin \[[@CR42], [@CR43]\] were included. As these trials had a treat-to-target design, people treated with degludec achieved non-inferior reductions in HbA~1c~ compared with those treated with IGlar U100.

The total end-of-trial daily insulin dose was either similar in each treatment group \[[@CR42], [@CR43], [@CR46]\] or statistically significantly lower (11--20%) in participants receiving degludec compared with IGlar U100 in people with T2D \[[@CR44], [@CR45]\].

A preplanned meta-analysis of seven trials of degludec compared with IGlar U100 demonstrated that people with T2D treated with degludec experienced significantly lower rates of overall and nocturnal confirmed hypoglycemic episodes {estimated rate ratios (ERRs) of 0.83 (95% confidence intervals \[CIs\] 0.74; 0.94) and 0.68 (95% CI 0.57; 0.82), respectively} \[[@CR34]\]. The SWITCH 2 crossover trial confirmed that participants with T2D treated with degludec had significantly lower rates of overall and nocturnal confirmed hypoglycemia than people treated with IGlar U100 (ERR of 0.70 \[95% CI 0.61; 0.80\] and 0.58 \[95% CI 0.46; 0.74\], respectively) \[[@CR31]\]. The proportion of participants experiencing at least one severe episode of hypoglycemia was also lower with degludec (1.6%) compared with IGlar U100 (2.4%), but the difference did not reach significance \[[@CR31]\]. SWITCH 2 demonstrated the safety of degludec in a high-risk population more reflective of everyday clinical practice as it enrolled participants who were at higher risk for hypoglycemia at baseline compared with the BEGIN trials, which had excluded participants with recurrent severe hypoglycemia or hypoglycemia unawareness.

Liraglutide Clinical Trials {#Sec9}
---------------------------

The efficacy and safety of liraglutide either as monotherapy or in combination with OADs was investigated in more than 4000 people with T2D in the LEAD clinical trial program \[[@CR47], [@CR48]\]. LEAD demonstrated that the administration of liraglutide once-daily led to significantly superior improvements in HbA~1c~ compared with a variety of OAD comparators, with a low rate of hypoglycemia (lower than sulfonylureas and IGlar U100, but higher than placebo and rosiglitazone) and relative reductions in body weight compared with most comparators \[[@CR49]--[@CR54]\]. However, treatment with liraglutide and other GLP-1RAs resulted in an increased incidence of GI adverse events, although these tended to be transient, decreasing over time \[[@CR49]--[@CR55]\].

Efficacy of Basal Insulin and GLP-1RA in Free Combination {#Sec10}
=========================================================

The complementary effects of free combinations of basal insulin and GLP-1RA therapy have been recognized for several years \[[@CR56]\]. As an example, the BEGIN: ADD TO GLP-1 study investigated the efficacy and safety of administering degludec, compared with placebo, to people with T2D who had not achieved an HbA~1c~ target of \< 7.0% (\< 53 mmol/mol) with metformin and maximum-dose liraglutide (1.8 mg). After 26 weeks, 78% of participants receiving degludec had achieved HbA~1c~ \< 7.0% (\< 53 mmol/mol) compared with 36% of participants receiving placebo \[[@CR57]\]. Another study investigated the effect of adding the basal insulin detemir to liraglutide and metformin in people with T2D with HbA~1c~ ≥ 7.0% (≥ 53 mmol/mol), and reported that 43% of participants achieved an HbA~1c~ target of \< 7.0% (53 mmol/mol) compared with 17% of participants receiving placebo \[[@CR58]\].

A 26-week, double-blind, parallel-group, placebo-controlled study investigated the effect of adding liraglutide to a pre-existing basal insulin analogue ± metformin in adults with inadequately controlled T2D (HbA~1c~ 7.0--10.0% \[53--86 mmol/mol\]) \[[@CR59]\]. After 26 weeks, 59% and 43% of participants achieved HbA~1c~ \< 7.0% (53 mmol/mol) or ≤ 6.5% (≤ 48 mmol/mol) with liraglutide, respectively, compared with 14% and 4% of participants receiving placebo, respectively. Liraglutide also resulted in significantly improved body weight and systolic blood pressure compared with placebo \[[@CR59]\].

A meta-analysis of 11 randomized controlled trials comparing free or fixed combinations of a GLP-1RA plus basal insulin with uptitration of basal insulin in people with T2D reported that the combination therapy led to a mean HbA~1c~ decrease significantly greater than insulin uptitration (− 0.5% \[− 6 mmol/mol\], 95% CI − 0.66; − 0.40, *p \< *0.001); more individuals at the HbA~1c~ target of \< 7.0% (relative risk \[RR\] 1.69, 95% CI 1.42; 2.00, *p \< *0.001); similar hypoglycemic events (RR 0.97, 95% CI 0.84; 1.12, *p* = 0.114); and reduction in body weight (− 1.9 kg, 95% CI − 2.3; − 1.4, *p \< *0.001). Results were consistent in both the free and fixed combination subgroups \[[@CR60]\].

IDegLira Clinical Trials {#Sec11}
========================

The phase III, DUAL clinical trial program has demonstrated the efficacy and safety of IDegLira in participants with T2D irrespective of prior GLP-1RA and insulin use (Table [1](#Tab1){ref-type="table"}). The primary endpoint for the DUAL I--VII and IX trials was change in HbA~1c~ from baseline to end of trial (EOT) (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR8], [@CR40], [@CR41], [@CR61]--[@CR65]\]. The key clinical findings from the DUAL program are summarized in Panel 1.Table 1Trial design for the DUAL phase III clinical trial program in type 2 diabetesPrevious treatment regimenDUAL trialStudy designPrevious regimen^a^HbA~1c~ range for inclusionComparatorsStarting doseMaximum doseTitration scheduleOAD(s)DUAL I26-Week, randomized, open-label (*N* = 1663)Metformin ± pioglitazone7.0--10.0% (53--86 mmol/mol)Degludec and liraglutide10 units/dose steps IDegLira; 10 units degludec; 0.6 liraglutideIDegLira titrated to a maximum 50 units/dose steps; degludec no maximum dose; liraglutide 1.8 mgIDegLira and degludec were titrated twice per week based on a pre-breakfast target SMBG of 4--5 mmol/LDUAL IV26-Week, randomized, double-blind (*N* = 435)SU ± metformin7.0--9.0% (53--75 mmol/mol)Placebo10 units/dose steps IDegLira; matching placeboIDegLira and placebo titrated to a maximum 50 units/dose stepsIDegLira and degludec were titrated twice per week based on a pre-breakfast target SMBG of 4--6 mmol/LDUAL VI32-Week, randomized, open-label (*N* = 420)Metformin ± pioglitazone7.0--10.0% (53--86 mmol/mol)Once-weekly IDegLira titration10 units/dose steps IDegLiraIDegLira titrated to a maximum 50 units/dose stepsIDegLira was titrated either once weekly or twice weekly based on a pre-breakfast target SMBG of 4--5 mmol/LDUAL VIII104-Week randomized, open-label (*N* = 1012)Metformin ± SU ± glinides ± pioglitazone ± DPP-4i7.0--11.0% (53--97 mmol/mol)IGlar U10010 units/dose steps IDegLira; 10 units of IGlar U100IDegLira titrated to a maximum 50 units/dose steps; IGlar U100 no maximum doseIDegLira was titrated twice weekly based on a pre-breakfast target SMBG of 4--5 mmol/LDUAL IX26-Week, randomized, open-label (*N* = 420)SGLT2i ± metformin ± DPP4i ± pioglitazone7.0--11.0% (53--97 mmol/mol)IGlar U10010 units/dose steps IDegLira; 10 units of IGlar U100IDegLira titrated to a maximum 50 units/dose steps; no maximum dose for IGlar, SGLT2i and OADIDegLira and IGlar U100 were titrated twice per week based on a pre-breakfast target SMBG of 4--5 mmol/LGLP-1RADUAL III26-Week, randomized, open-label (*N* = 438)GLP-1RA + metformin ± SU ± glinides ± pioglitazone7.0--9.0% (53--75 mmol/mol)Pre-trial liraglutide or exenatide16 units/dose steps IDegLira; pre-trial dose (maximum dose) of GLP-1RAIDegLira titrated to a maximum 50 units/dose stepsIDegLira was titrated twice per week based on a pre-breakfast target SMBG of 4--5 mmol/LBasal insulinDUAL II26-Week, randomized, double-blind (*N* = 413)Basal insulin (20--40 U) + metformin ± SU or glinides7.5--10.0% (59--86 mmol/mol)Degludec16 units/dose steps IDegLira; 16 units degludecIDegLira titrated to a maximum 50 units/dose steps; degludec had a maximum dose of 50 unitsIDegLira and degludec were titrated twice weekly based on a pre-breakfast target SMBG of 4--5 mmol/LDUAL V26-Week, randomized, open-label (*N* = 557)Metformin + IGlar U100 (20--50 U)7.0--10.0% (53--86 mmol/mol)IGlar U10016 units/dose steps IDegLira; pre-trial dose of IGlarIDegLira titrated to a maximum 50 units/dose steps; IGlar U100 no maximum doseIDegLira and IGlar U100 were titrated twice weekly based on a pre-breakfast target SMBG of 4--5 mmol/LDUAL VII26-week, randomized, open-label (*N* = 506)Metformin + IGlar U100 (20--50 U)7.0--10.0% (53--86 mmol/mol)IGlar U100 + IAsp (≤ 4 times)16 units/dose steps IDegLira; IGlar U100 at a dose equivalent to the pre-trial dose; IAsp at 4 units at each main mealIDegLira titrated to a maximum 50 units/dose steps; no maximum dose for IGlar U100 or IAspIDegLira and IGlar U100 were titrated twice weekly, aiming for a mean fasting SMBG target range of 4.0--5.0 mmol/L; IAsp was titrated twice weekly, aiming for a mean pre-prandial and bedtime SMBG target range of 4.0--6.0 mmol/L*DPP4i* dipeptidyl peptidase-4 inhibitor, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HbA*~*1c*~ glycated hemoglobin, *IAsp* insulin aspart, *IDegLira* insulin degludec/liraglutide, *IGlar* insulin glargine, *OAD* oral antidiabetic therapy, *SMBG* self-measured blood glucose, *SGLT2i* sodium-glucose co-transporter 2 inhibitor, *SU* sulfonylureas, *U* units of insulin^a^DPP-4 inhibitors in DUAL IX were discontinued at randomization, but all other OADs were continued at pre-trial doses, unless there was a safety concernFig. 1Key findings from the DUAL program **a** change in HbA~1c~ at EOT; **b** rates of hypoglycemia; **c** change in body weight at EOT; and **d** insulin dose at EOT \[[@CR8], [@CR40], [@CR41], [@CR61]--[@CR65]\]. \*Statistically significant for non-inferiority. \*\*Statistically significant for superiority; degludec was capped at 50 units in the DUAL II trial. DUAL VIII data have been excluded as a result of the 104-week durability trial design, which is not directly comparable with the other DUAL studies. *1WT* once-weekly titration, *2WT* twice-weekly titration, *CI* confidence interval, *EOT* end of trial, *ERR* estimated rate ratio, *ETD* estimated treatment difference, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HbA*~*1c*~ glycated hemoglobin, *IAsp* insulin aspart, *IDegLira* insulin degludec/liraglutide, *IGlar* insulin glargine, *NR* not reported, *OAD* oral antidiabetic therapy, *PYE* participant-year exposure, *U* units of insulin**Panel 1:** Key Clinical Learnings from the DUAL Program• IDegLira provides reductions in HbA~1c~ to all patient groups with T2D regardless of their prior treatment (DUAL I--VII and IX)• Despite this level of glucose-lowering efficacy, people randomized to IDegLira experienced fewer hypoglycemic episodes compared with those treated with basal or basal--bolus insulin therapy (DUAL I, II, V, VII, and IX)• On average, people transferring from basal insulin to IDegLira experienced beneficial body weight reduction or stabilization, compared with people treated with continued basal or basal--bolus therapy (DUAL II, V and VII)• IDegLira is associated with a lower incidence of GI adverse events compared with liraglutide or exenatide (DUAL I extension and DUAL III)• IDegLira is an efficacious treatment option for people who do not achieve sufficient glycemic control with regimens containing sulfonylureas with or without metformin or basal insulin with or without metformin (DUAL IV, V and VII)• Insulin-naïve people with T2D experienced greater durability of glycemic control when treated with IDegLira compared with IGlar U100 (DUAL VIII)• IDegLira has a simple intensification regimen for people with T2D not reaching their glycemic targets on injectable therapy, as it enables intensification without additional daily injections (DUAL II, III, V, and VII)• People switching to using IDegLira instead of adding bolus insulin to a basal insulin-based regimen can avoid the inconvenience of multiple daily insulin injections and reduce their total daily insulin dose in addition to benefiting from reductions in body weight and HbA~1c~ (DUAL VII)*HbA*~*1c*~, glycated hemoglobin, *GI* gastrointestinal, *GLP-1RA* glucagon-like peptide-1 receptor agonists, *IDegLira* insulin degludec/liraglutide, *IGlar* insulin glargine, *T2D* type 2 diabetes

Insulin-Naïve People Receiving Antidiabetes Drugs (OADs) {#Sec12}
--------------------------------------------------------

Five trials investigated the efficacy and safety of IDegLira as an add-on to OADs, in people who were insulin-naïve with inadequate glycemic control (Table [1](#Tab1){ref-type="table"}).

### DUAL I: IDegLira Compared with Both Degludec and Liraglutide {#Sec13}

DUAL I was a 26-week, randomized, open-label, parallel-group trial that compared the efficacy and safety of IDegLira with its components, degludec and liraglutide, in combination with metformin with or without pioglitazone (Table [1](#Tab1){ref-type="table"}). IDegLira was found to be non-inferior to degludec and superior to liraglutide in reduction in HbA~1c~ from baseline to EOT (Fig. [1](#Fig1){ref-type="fig"}a). Participants treated with IDegLira experienced fewer episodes of hypoglycemia, body weight loss compared with body weight gain, and a lower insulin dose (Fig. [1](#Fig1){ref-type="fig"}b--d), but higher rates of GI adverse events when compared with participants treated with degludec (Table [2](#Tab2){ref-type="table"}). Participants treated with IDegLira experienced more episodes of hypoglycemia and a reduced effect on weight loss (Fig. [1](#Fig1){ref-type="fig"}b, c), but with a lower rate of GI adverse events when compared with participants treated with liraglutide (Table [2](#Tab2){ref-type="table"}) \[[@CR8]\].Table 2Gastrointestinal adverse events in participants in the DUAL clinical trial programPrevious treatment regimenDUAL trialTreatment groupNausea (events per 100 PYE)Diarrhea (events per 100 PYE)Vomiting (events per 100 PYE)OAD(s)DUAL IIDegLira20.923.510.1Degludec8.810.33.1Liraglutide54.339.823.6DUAL IVIDegLira11.310.55.3Placebo8.012.96.4DUAL VIIDegLira 1WT13.14.93.3IDegLira 2WT15.75.53.1DUAL VIIIIDegLira4.96.42.9IGlar U1001.42.21.7DUAL IXIDegLira21.312.64.8IGlar U1001.97.63.8GLP-1RADUAL IIIIDegLira7.812.82.8Pre-trial liraglutide or exenatide10.613.79.1Basal insulinDUAL IIIDegLira21.822.89.8Degludec7.88.9NRDUAL VIDegLira26.217.717.0IGlar U1002.27.43.7DUAL VIIIDegLira30.719.910.0IGlar U100 + IAsp (≤ 4 times)3.414.25.9*1WT* once-weekly titration, *2WT* twice-weekly titration, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *IAsp* insulin aspart, *IDegLira* insulin degludec/liraglutide, *IGlar* insulin glargine, *NR* not reported, *OAD* oral antidiabetic therapy, *PYE* participant-year exposure

### DUAL IV: IDegLira Compared with Placebo {#Sec14}

DUAL IV was a 26-week, randomized, double-blind, parallel-group trial that assessed the efficacy and safety of IDegLira as an add-on to sulfonylurea therapy (Table [1](#Tab1){ref-type="table"}). Mean reduction of HbA~1c~ from baseline was superior for participants who received IDegLira compared with placebo (Fig. [1](#Fig1){ref-type="fig"}a). The rate of confirmed hypoglycemia was higher with IDegLira than with placebo and the two events of severe hypoglycemia reported in the trial both occurred in the IDegLira treatment group (*n *= 289) (Fig. [1](#Fig1){ref-type="fig"}b). The rate of hypoglycemia observed with IDegLira in DUAL IV was higher than that observed in other trials in the DUAL program and may be attributed to the effect of sulfonylurea therapy, which is associated with an increased risk of hypoglycemia (and weight gain), especially when combined with insulin therapy. There was no significant difference in the rates of nocturnal hypoglycemia between the treatment groups. Participants treated with IDegLira experienced a body weight gain compared with a body weight loss with placebo (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR63]\].

### DUAL VI: IDegLira Once-Weekly Compared with Twice-Weekly Titration {#Sec15}

DUAL VI was a 32-week, randomized, open-label, parallel-group trial that assessed the efficacy and safety of IDegLira as an add-on to existing OAD therapy when titrated using a pragmatic once-weekly algorithm, compared with twice-weekly titration (Table [1](#Tab1){ref-type="table"}), as recommended in current prescribing information \[[@CR7], [@CR66]\]. Mean reduction in HbA~1c~ in the once-weekly titration group was non-inferior to twice-weekly titration (Fig. [1](#Fig1){ref-type="fig"}a). Participants in both the once- and twice-weekly titration arms experienced low rates of hypoglycemia (Fig. [1](#Fig1){ref-type="fig"}b) and were receiving the same dose of IDegLira at EOT (Fig. [1](#Fig1){ref-type="fig"}d). Participants who titrated IDegLira twice weekly achieved a significantly greater reduction in body weight compared with those who titrated IDegLira once weekly (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR64]\].

### DUAL VIII: IDegLira Compared with IGlar U100 {#Sec16}

DUAL VIII was a 104-week, open-label durability trial, comprising an initial 26 weeks where participants were titrated with either IDegLira or IGlar U100 to the HbA~1c~ target of \< 7.0% (53 mmol/mol), followed by 78 weeks of monitoring (Table [1](#Tab1){ref-type="table"}). The primary endpoint was time from randomization to inadequate glycemic control and need for treatment intensification, defined as HbA~1c~ ≥ 7.0% (53 mmol/mol) at two consecutive visits from week 26 (including week 26 if HbA~1c~ was ≥ 7.0% \[53 mmol/mol\] at week 12) up to 104 weeks. Participants treated with IDegLira had a longer time to 'need for treatment intensification' (median \> 2 years) compared with IGlar U100 (median approximately 1 year; *p \< *0.0001 accounting for baseline HbA~1c~ group and background sulfonylurea use as baseline strata). Furthermore, 63% of participants treated with IDegLira did not require treatment intensification by week 104 compared with 34% of participants treated with IGlar U100. In addition to improved durability, participants in the IDegLira group also had a lower insulin dose (37 units compared with 52 units; estimated treatment difference \[ETD\] − 14.9; 95% CI − 17.4; − 12.5; *p \< *0.0001), less body weight gain (1.7 compared with 3.4 kg; ETD − 1.70; 95% CI − 2.47; − 0.93; *p \< *0.0001), and experienced a lower incidence of hypoglycemia (0.38 compared with 0.86 events per PYE; ERR 0.44; 95% CI 0.33; 0.60; *p \< *0.0001) than participants in the IGlar U100 group, had treatment intensification not been needed. No new safety signals were observed over the 2-year trial period \[[@CR67]\].

### DUAL IX: IDegLira Compared with IGlar U100 {#Sec17}

This 26-week, open-label trial aimed to investigate the efficacy and safety of IDegLira as an add-on to a sodium-glucose transport protein 2 inhibitor (Table [1](#Tab1){ref-type="table"}). Participants treated with IDegLira achieved a superior reduction in mean HbA~1c~ from baseline to EOT compared with IGlar U100 (Fig. [1](#Fig1){ref-type="fig"}a). Participants in the IDegLira treatment arm experienced significantly lower rates of hypoglycemia and less body weight gain compared with IGlar U100 (Fig. [1](#Fig1){ref-type="fig"}b, c). At the end of the study, participants in the IDegLira arm were receiving a significantly lower mean daily insulin dose than participants treated with IGlar U100 (Fig. [1](#Fig1){ref-type="fig"}d) \[[@CR65]\].

Insulin-Naïve People Receiving GLP-1RAs in Combination with OADs: IDegLira Compared with GLP-1RA {#Sec18}
------------------------------------------------------------------------------------------------

The aim of DUAL III, a 26-week, randomized, open-label trial, was to investigate the efficacy of IDegLira in controlling glycemia in adults whose T2D was inadequately controlled on GLP-1RA and OAD therapy (Table [1](#Tab1){ref-type="table"}). Compared with unchanged GLP-1RA therapy, IDegLira was associated with a superior reduction in HbA~1c~, a higher rate of hypoglycemia and a mean body weight gain compared with a mean body weight loss (Fig. [1](#Fig1){ref-type="fig"}a--c). However, participants treated with IDegLira had a lower rate of GI adverse events than those treated with unchanged GLP-1RA therapy (Table [2](#Tab2){ref-type="table"}) \[[@CR62]\].

People Receiving Basal Insulin and OADs {#Sec19}
---------------------------------------

Three trials investigated the efficacy of IDegLira in people switching from a basal insulin regimen (20--40 units or 20--50 units) to IDegLira, compared with continuation with a basal insulin regimen, in combination with metformin, or initiation of a basal--bolus regimen \[[@CR40], [@CR41], [@CR61]\].

### DUAL II: IDegLira Compared with Degludec {#Sec20}

DUAL II was a 26-week, randomized, parallel, double-blind, treat-to-target trial comparing the efficacy and safety of IDegLira with the basal insulin degludec (maximum 50 units), both in combination with metformin (Table [1](#Tab1){ref-type="table"}). All pretrial glucose-lowering drugs were discontinued, except metformin. Participants treated with IDegLira experienced a superior reduction in HbA~1c~ compared with those treated with degludec (Fig. [1](#Fig1){ref-type="fig"}a). Furthermore, participants treated with IDegLira experienced a similar rate of confirmed hypoglycemia compared with degludec (Fig. [1](#Fig1){ref-type="fig"}b), and there was one severe hypoglycemic event in DUAL II, in a participant receiving IDegLira. The rate of nocturnal hypoglycemia observed in participants treated with IDegLira did not differ between groups, nor did the total EOT insulin dose between the degludec monotherapy and IDegLira treatment arms in this dose-capped study (Fig. [1](#Fig1){ref-type="fig"}d). IDegLira was associated with an average decrease in body weight compared with no change in body weight with degludec (Fig. [1](#Fig1){ref-type="fig"}c) \[[@CR61]\].

### DUAL V: IDegLira Compared with IGlar U100 {#Sec21}

DUAL V was a 26-week, randomized, treat-to-target trial that compared the efficacy of IDegLira and IGlar U100 in individuals who had insufficient glycemic control while taking metformin and IGlar U100 (20--50 U) (Table [1](#Tab1){ref-type="table"}). Participants randomized to IGlar U100 started the trial on their pretrial dose and uptitrated their treatment over the course of the trial, as required. Participants treated with IDegLira experienced a superior reduction in mean HbA~1c~ compared with IGlar U100 uptitration (Fig. [1](#Fig1){ref-type="fig"}a), while participants treated with IDegLira had significantly fewer episodes of confirmed hypoglycemia than those treated with the comparator (Fig. [1](#Fig1){ref-type="fig"}b). Only one participant who was receiving IGlar U100 experienced severe hypoglycemia in DUAL V. Participants treated with IDegLira were statistically significantly at less risk of experiencing confirmed nocturnal hypoglycemia than people treated with IGlar U100. There was a significant reduction in the total daily insulin dose, and participants in the IDegLira group experienced body weight loss compared with those in the IGlar U100 group, who experienced body weight gain (Fig. [1](#Fig1){ref-type="fig"}c, d) \[[@CR41]\].

### DUAL VII: IDegLira Compared with Multiple Daily Insulin Injections (MDIs) {#Sec22}

DUAL VII was a 26-week, open-label, two-arm parallel, randomized, treat-to-target trial. It investigated the efficacy and safety of IDegLira compared with multiple daily insulin injections (MDIs; basal insulin IGlar U100 combined with bolus insulin aspart \[IAsp\] ≤ 4 times daily), in people with T2D not reaching their glycemic targets with basal insulin (Table [1](#Tab1){ref-type="table"}). Participants experienced similar reductions in HbA~1c~ in both the IGlar U100 and IAsp and IDegLira treatment arms (Fig. [1](#Fig1){ref-type="fig"}a). Participants treated with IDegLira had significantly fewer episodes of confirmed hypoglycemia than those treated with the comparator (Fig. [1](#Fig1){ref-type="fig"}b). Furthermore, participants treated with IDegLira had fewer episodes of severe hypoglycemia and nocturnal hypoglycemia compared with IGlar U100 and IAsp. Participants treated with IDegLira were receiving a significantly lower insulin dose at EOT than those treated with IGlar U100 and IAsp (Fig. [1](#Fig1){ref-type="fig"}c). IDegLira was also associated with body weight loss compared with body weight gain in the IGlar U100 and IAsp arm (Fig. [1](#Fig1){ref-type="fig"}d) \[[@CR40]\].

People Not Tolerating MDI Regimens {#Sec23}
----------------------------------

While the efficacy of IDegLira has been compared with MDIs in the DUAL VII trial, the efficacy of switching from an MDI regimen to an IDegLira regimen has not yet been investigated in a clinical trial setting. However, real-world data have demonstrated the effectiveness of IDegLira in individuals who had switched from MDIs.

The EXTRA study, a real-world retrospective chart review, collected data on 173 people receiving MDIs ± OADs who switched to treatment with IDegLira \[[@CR68]\]. Over 6 months of treatment, these people had a mean 0.7% (8 mmol/mol) reduction in HbA~1c~ (from 8.3% \[67 mmol/mol\] to 7.6% \[60 mmol/mol\]; *p \< *0.0001), which was accompanied by a 31% reduction in daily insulin dose (from 65 units to 45 units; *p \< *0.0001), and a 2.4-kg decrease in body weight (from a baseline of 102.3 kg; *p \< *0.0001) \[[@CR68]\]. This observational study suggests that people switching to IDegLira from an MDI regimen can avoid the inconvenience of multiple daily injections, reducing total daily insulin dose in addition to experiencing beneficial changes in body weight and HbA~1c~.

Cardiovascular (CV) Safety {#Sec24}
--------------------------

US FDA guidelines \[[@CR69]\] require an assessment of cardiovascular (CV) safety for all new diabetes drugs. Although a CV outcome trial (CVOT) has not been conducted in people treated with IDegLira, CVOTs have been conducted on the individual components: degludec (DEVOTE \[[@CR33]\]) and liraglutide (LEADER \[[@CR70]\]). DEVOTE demonstrated that degludec was non-inferior to glargine with respect to the incidence of major CV events (MACE) in participants with T2D at high risk for CV events (*n* = 7637) \[[@CR33]\]. A post hoc analysis of participants in DEVOTE, which compared outcomes between participants concomitantly treated with liraglutide with those who had no liraglutide use, found that participants treated with degludec or IGlar U100 with liraglutide had significantly fewer MACE compared with participants in the degludec/IGlar U100 without liraglutide group (hazard ratio \[HR\] 0.62, 95% CI 0.41; 0.92; *p* = 0.02 \[[@CR71]\]). This observation suggested that liraglutide might have CV benefits for people treating their T2D with basal insulin.

The LEADER trial demonstrated that participants with T2D at high risk for CV disease (*n* = 9340) receiving subcutaneous injections of liraglutide 1.8 mg had a lower risk of CV events and death from any cause than those receiving placebo \[[@CR70]\]. Results of a post hoc analysis of LEADER that compared participants receiving no insulin treatment, basal-only insulin, or other insulin in addition to liraglutide suggest that the relative cardioprotection of liraglutide (compared with placebo) is preserved, at least in participants also using basal insulin; however, it should be noted that the study was not designed and powered for these post hoc analyses \[[@CR72]\].

In addition to the DEVOTE and LEADER trials, further information on the effect of IDegLira on known CV risk factors beyond blood glucose has been provided by post hoc analyses of the DUAL II, V, and VII studies \[[@CR73]\]. These analyses found that participants treated with IDegLira experienced a greater decrease in mean systolic blood pressure, consistently lower or equal levels of low-density lipoprotein (LDL), and a small but statistically significant increase in heart rate, compared with the basal insulin comparators. In the DUAL II trial, no differences between treatments were seen for high-sensitivity C-reactive protein, whereas apolipoprotein B and brain natriuretic peptide were significantly lower with IDegLira compared with degludec after 26 weeks \[[@CR73]\].

Taken together, these data indicate that IDegLira is associated with a general improvement in CV risk markers compared with basal insulin or basal--bolus therapy \[[@CR73]\].

*Key clinical learning* The components of IDegLira have confirmed non-inferiority (degludec compared with IGlar U100) and superiority (liraglutide compared with placebo), in terms of incidence of MACE in their respective CVOTs \[[@CR33], [@CR70]\]. Additionally, there is evidence of a general improvement in CV risk markers in people treated with IDegLira compared with participants treated with basal insulin \[[@CR73]\].

Cost-Effectiveness Analysis of IDegLira {#Sec25}
=======================================

The cost effectiveness of treatment interventions is a key consideration when choosing therapies for people with T2D. Direct comparison of the acquisition costs of different therapies is insufficient to inform healthcare payer decision making as there are multiple factors to consider aside from achieving glycemic control, including the likelihood and burden of adverse events such as hypoglycemia and body weight gain, quality of life, and, importantly, the prognosis for diabetes-related micro- and macrovascular complications \[[@CR74]--[@CR76]\].

Short- and long-term cost-effectiveness analyses of IDegLira in comparison with uptitration of IGlar U100 and basal--bolus therapy of IGlar U100 and IAsp, have been conducted \[[@CR74]--[@CR79]\]. Based on clinical trial data from both the US and the UK, IDegLira has been shown to provide a cost-effective treatment option in people with uncontrolled T2D (Table [3](#Tab3){ref-type="table"}) \[[@CR74]--[@CR79]\]. In the analyses where IDegLira was associated with increased costs, incremental cost-effectiveness ratios remained well below the US value-based price benchmark of \$100,000--\$150,000 per quality-adjusted life-year (QALY) gained suggested by the Institute for Clinical and Economic Review, or the commonly accepted willingness-to-pay threshold of £20,000--£30,000/QALY in the UK (Table [3](#Tab3){ref-type="table"}). The short-term cost of control analyses (cost per person achieving treatment targets) have reported lower or equivalent annual costs of control with IDegLira in comparison with basal--bolus therapy or basal insulin uptitration, both for glycemic targets (HbA~1c~ ≤ 6.5% \[≤ 48 mmol/mol\] or \< 7.0% \[\< 53 mmol/mol\]) singularly and for composite endpoints without hypoglycemia and/or body weight gain \[[@CR75], [@CR79]\]. For example, in an analysis of the full DUAL V trial population, the annual cost per participant achieving a target of HbA~1c~ ≤ 6.5% (48 mmol/mol) was lower with IDegLira than with continued uptitration of IGlar U100 (\$18,556 compared with \$21,862); however, the cost per participant achieving HbA~1c~ \< 7.0% (53 mmol/mol) was similar in the two arms (\$14,358 compared with \$14,327) \[[@CR75]\].Table 3Treatment costs associated with IDegLira compared with basal or basal--bolus insulin regimensTreatmentsAnnual per participant difference in costs (\$)^a^Total cost savings over a participant's lifetimeICER (life expectancy) per life-year gainedICER (quality-adjusted life expectancy) per QALY gainedIDegLira compared with uptitrated IGlar U100 Davies et al. 2016 \[[@CR78]\]--£1441£7130£6090 Hunt et al. 2017 \[[@CR74]\]--\$16,970\$96,039\$63,678 Hunt et al. 2017 \[[@CR75]\]\$3546------IDegLira compared with IGlar U100 + IAsp Davis et al. 2016 \[[@CR78]\]--£1698IDegLira dominantIDegLira dominant Dempsey et al. 2018 \[[@CR77]\]--\$3571IDegLira dominantIDegLira dominant \[\$4050^b^\] Dempsey et al. 2018 \[[@CR77]\]−\$743.44 \[+ \$267.97^a^\]----IDegLira dominant \[\$2211^b^\] Drummond et al. 2018 \[[@CR76]\]+£303 \[+ £794^a^\]----£5924 \[£15,505^b^\]*IAsp* insulin aspart, *IDegLira* insulin degludec/liraglutide, *IGlar* insulin glargine, *QALY* quality-adjusted life-year, *ICER* incremental cost-effectiveness ratio, *SMBG* self-measured blood glucose^a^Total annual treatment cost, unless stated otherwise^b^Values derived from sensitivity analysis in which needle and SMBG costs were excluded

Use of IDegLira in Clinical Practice {#Sec26}
====================================

Initiation {#Sec27}
----------

IDegLira is given as a once-daily subcutaneous injection, which can be administered at any time of the day, but preferably around the same time each day \[[@CR7]\]. People not reaching glycemic targets while receiving OADs, GLP-1RAs, and basal insulin can successfully switch to IDegLira, as described in the DUAL trials \[[@CR8], [@CR40], [@CR41], [@CR61]--[@CR63], [@CR65]\] (Fig. [1](#Fig1){ref-type="fig"}).

The people who may benefit from a GLP-1RA and basal insulin FRC therapy based on our expert opinion are described in Panel 2, while information on how best to initiate IDegLira is provided in Fig. [2](#Fig2){ref-type="fig"}.Fig. 2IDegLira initiation algorithm to provide guidance for physicians based on prior therapy of individuals with T2D. *DPP-4i* dipeptidyl peptidase 4 inhibitor, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *IDegLira* insulin degludec/liraglutide, *OAD* oral antidiabetic drug, *SU* sulfonylurea**Panel 2:** Clinical Profiles for People with T2D and Consideration for use of GLP-1RA/Basal Insulin FRC TherapyWe recommend GLP-1RA/basal insulin FRCs such as IDegLira be considered as a first injectable therapy for people with T2DGLP-1RA/basal insulin FRCs should also be considered as an alternative for people with T2D not reaching their glycemic targets when treated with:• GLP-1RA monotherapy• Basal insulin---in people who might otherwise require intensification with MDIs• Twice-daily basal insulin---in people with recurrent hypoglycaemia• MDIs^aa^The use of IDegLira in people with T2D receiving MDIs is not approved and has not been investigated in a clinical trial*HbA*~*1c*~, glycated hemoglobin, *FRC* fixed ratio combination, *GLP-1RA* glucagon-like peptide-1 receptor agonists, *IDegLira* insulin degludec/liraglutide, *MDI*s multiple daily insulin injections, *T2D* type 2 diabetes

### Addition of IDegLira for People Not Reaching Targets While Taking OADs {#Sec28}

IDegLira is licensed in Europe and the US as an addition to OAD for people not reaching glycemic targets \[[@CR7], [@CR66]\]. In these people, IDegLira should be initiated at 10 units/dose steps.

Most OADs can be continued when initiating IDegLira without modification. DPP-4 inhibitors are not contraindicated in people initiating IDegLira \[[@CR7], [@CR66]\]; however, the combination of DPP-4 inhibitors with GLP-1RAs has no observed clinical benefit \[[@CR80]\] and therefore we recommend discontinuation of DPP-4 inhibitors when initiating IDegLira.

People can continue treatment with pioglitazone when initiating IDegLira, but it is important to note that cases of cardiac failure have been reported when pioglitazone has been combined with insulin products, particularly in people with CV risk factors. Therefore, if pioglitazone is continued when IDegLira is initiated, these individuals should be closely monitored for symptoms of heart failure, body weight gain, and edema. If any of these symptoms or signs occur, pioglitazone should be discontinued \[[@CR7]\].

Sulfonylureas can be continued in individuals when IDegLira is initiated, as demonstrated by the DUAL IV trial that assessed the efficacy and safety of IDegLira in people with T2D as an add-on to pretrial sulfonylurea (with or without metformin; Table [1](#Tab1){ref-type="table"} \[[@CR63]\]); however, a reduction in dose and a plan to discontinue should be considered for those close to their glycemic target to reduce the risk of hypoglycemia and body weight gain associated with combining basal insulin or GLP-1RAs with sulfonylureas \[[@CR7], [@CR36]\]. A post hoc analysis of the DUAL II trial grouped participants by pretrial sulfonylurea use to investigate glycemic control in those who switched to IDegLira. This analysis demonstrated that participants who discontinued sulfonylureas and initiated IDegLira experienced no loss of glycemic control in the weeks after switching to IDegLira, and reached good glycemic control by week 26 regardless of pretrial sulfonylurea use \[[@CR81]\]. While the rates of hypoglycemia were higher in people treated with IDegLira and sulfonylureas concurrently compared with placebo, the rate was the same order of magnitude as recorded in other studies where people were treated concomitantly with sulfonylureas and basal insulin \[[@CR45], [@CR65], [@CR82]\]. Clinicians should always consider stopping sulfonylurea therapy when combining with insulin, particularly when treatment with IDegLira is initiated.

*Key clinical learning* Most OADs can be continued when initiating IDegLira without modification; however, we recommend the discontinuation of DPP-4 inhibitors and a reduction in the dose of sulfonylureas, as well as a plan for discontinuation, when initiating IDegLira. People receiving pioglitazone treatment should be closely monitored for edema and heart failure when initiating IDegLira.

### Switching from GLP-1RA or Basal Insulin to IDegLira {#Sec29}

Prior basal insulin or GLP-1RA therapy should be discontinued prior to the initiation of IDegLira. The recommended starting dose of IDegLira in this group of people is 16 units/dose steps (16 units degludec and 0.6 mg liraglutide) \[[@CR7], [@CR66]\]. Although 16 units/dose steps of IDegLira is likely to be a decrease in the total daily insulin dose in people transferring from basal insulin, because of the complementary actions of the two components, glycemic control can be achieved at a lower insulin dose \[[@CR8]\]. Furthermore, it is simple to titrate the dose of IDegLira, if necessary.

A post hoc analysis of the DUAL V trial investigated participant outcomes by pretrial insulin dose (20 to \< 30, 30 to \< 40 and 40 to ≤ 50 units/day) and demonstrated that, regardless of pretrial dose, participants treated with IDegLira achieved a significantly greater reduction in HbA~1c~ from baseline to EOT, compared with IGlar U100 \[[@CR83]\]. There was also no clinically significant increase in self-measured blood glucose (SMBG) in any pretrial dose group when switching to IDegLira, and no withdrawals due to hyperglycemia with IDegLira in the first 8 weeks following the switch \[[@CR83]\]. Furthermore, results from a real-world population of people with T2D (92% of whom were being treated with insulin) demonstrated that switching to IDegLira resulted in improved glucose control and body weight loss \[[@CR84]\]. The data from both clinical trials and real-world studies therefore suggest that IDegLira can be an effective and often superior substitution for any basal insulin dose \[[@CR83], [@CR84]\]. Additionally, results from DUAL VII demonstrate that in people whose diabetes was not controlled with basal insulin, IDegLira provides comparable HbA~1c~ reductions as basal--bolus insulin, with significantly lower hypoglycemia rates and weight loss compared with weight gain \[[@CR40]\]. People requiring basal--bolus insulin can represent a challenging patient population, as initiation and intensification of basal--bolus insulin can have limited success in terms of achieving HbA~1C~ targets, and is often associated with increased rates of hypoglycaemia and increased weight. Furthermore, treatment with IDegLira provides a simple, less burdensome injectable therapy compared with basal--bolus insulin, and this may help with taking medication \[[@CR85]\].

HCPs may be concerned that IDegLira has a maximum dose of 50 units/dose steps \[[@CR7], [@CR66]\], compared with no maximum doses for IGlar U100 and degludec. However, data from the DUAL studies demonstrate that the majority of participants (≥ 60%) treated with IDegLira achieved the HbA~1c~ target of \< 7.0% (\< 53 mmol/mol) at ≤ 50 units/dose steps. Additionally, the EXTRA real-world chart review of people with T2D found that only 67 (12%) people reached or exceeded the maximum dose (50 units/dose steps) of IDegLira either at initiation or at 6 months of follow-up \[[@CR68]\].

*Key clinical learning* People with T2D switching from GLP-1RAs or basal insulin to IDegLira will need to discontinue their prior therapy and initiate IDegLira at 16 units/dose steps. Studies have shown that although this might require a temporary reduction in dose, there was no long-term loss of glycemic control.

### Initiation of IDegLira in People with CV Risk {#Sec30}

There are currently no guidelines that specifically recommend IDegLira in the treatment of people with T2D and CV risk.

The results of several early CVOTs showed that lowering HbA~1c~ has a major beneficial impact on reducing microvascular complications in diabetes, but no clear benefit was seen on macrovascular disease \[[@CR86]--[@CR91]\]. Despite longer-term studies establishing a positive legacy effect of tight glycemic control on CV outcomes \[[@CR15], [@CR92]\], an increase in CV mortality was reported in high-risk individuals (those with additional CV risk factors) assigned to intensive glucose control in the ACCORD trial \[[@CR90], [@CR93]\]. Thus, guidelines recommend that targets are individualized to the needs of each person with diabetes and his or her disease factors \[[@CR19]\].

The most recent American Diabetes Association (ADA)/European Association for the Study of Diabetes consensus statement recommends GLP-1RA treatment, particularly liraglutide, as an early step for the intensification of therapy in T2D in people with established atherosclerotic CV disease \[[@CR3]\]. It should be noted that this recommendation is based on evidence from the LEADER CVOT, which examined the CV effect of once-daily liraglutide 1.8 mg \[[@CR70]\]; thus, it is not yet known if lower doses of liraglutide provide the same CV benefits. If individuals with T2D still do not reach their glycemic targets, the consensus ADA statement recommends further intensification, with the initiation of basal insulin therapy with either degludec or IGlar U100 listed as potential options, as a result of their documented CV safety profiles \[[@CR3]\].

Titration {#Sec31}
---------

The need for titration is a potential cause of therapeutic inertia and thus a barrier to achievement of good glycemic control. It is important that IDegLira is titrated to a therapeutic dose, but fortunately the titration method is quite simple and does not require carbohydrate counting. It is recommended in the product label that the dose of IDegLira is adjusted twice weekly, in increments of 2 units/dose steps, based on three consecutive FPG readings (Fig. [3](#Fig3){ref-type="fig"}) \[[@CR7], [@CR66]\]. However, the DUAL VI trial found that once-weekly titration of IDegLira was non-inferior in terms of glycemic control \[[@CR64]\], thus offering clinicians and people with diabetes different titration options.Fig. 3Twice-weekly dose titration recommendations for IDegLira. ^a^FPG measurement must be from the proceeding 3 days. *FPG* fasting plasma glucose, *IDegLira* insulin degludec/liraglutide

Titration of IDegLira was critical to achieving the glycemic control observed in the DUAL trials. Participants initiated IDegLira at a low dose (10 or 16 units/dose steps, depending on prior therapy \[[@CR7], [@CR66]\]), but reached approximately 40 units/dose steps over the 26- or 32-week trials, and this dose was required to achieve the reported reductions in HbA~1c~. Real-world data from the EXTRA study demonstrated that IDegLira titration in clinical practice is not as aggressive as in the clinical trials, with people with T2D reaching an average dose of 30 units/dose steps after 6 months of treatment, despite starting at a higher dose at initiation, achieving a mean HbA~1c~ of 7.5% (59 mmol/mol) \[[@CR68]\].

The initiation of IDegLira at a low dose, followed by titration, reduces the incidence of GI adverse events usually observed with GLP-1RAs. GI adverse events were a common cause of discontinuation for liraglutide therapy in DUAL I, whereas participants treated with IDegLira were less likely to discontinue as a result of adverse events (5.8% compared with 1.2%, respectively) \[[@CR8]\]. As a result of the need to initiate IDegLira at a low dose, it can take several weeks for individuals with T2D to reach their HbA~1c~ targets. The DUAL trials demonstrated that people with T2D can reach their HbA~1c~ target of \< 7.0% (\< 53 mmol/mol) at approximately 8--16 weeks \[[@CR8], [@CR40], [@CR41], [@CR61]--[@CR65]\], at a dose of approximately 40 units/dose steps.

In people with diabetic retinopathy and poor long-term glycemic control, intensification of therapy with insulin has been associated with the worsening of their condition \[[@CR94]\]. This risk appears to be associated with rapid reduction of blood glucose levels. Therefore, we think that HCPs should consider less aggressive titration of IDegLira in these people as this may avoid their condition worsening unnecessarily.

*Key clinical learning* It is important to monitor FPG levels and adjust the dose of IDegLira, in increments of 2 units/dose steps, to achieve the levels of glycemic control seen in the DUAL trials. However, less aggressive titration may be required in people with diabetic retinopathy and poor long-term glycemic control.

Conclusions {#Sec32}
===========

Therapeutic inertia is a real and ongoing challenge, particularly when initiating and intensifying insulin therapies in people who would benefit from an HbA~1c~ goal of \< 7.0% (53 mmol/mol). This inertia may in part be due to concerns of people with T2D and HCPs around hypoglycemia, body weight gain, and treatment and titration complexity. Combination therapies, such as IDegLira, offer the opportunity to improve efficacy with better outcomes for body weight and hypoglycemia compared with other insulin-based regimens.

Current guidance recommends the initiation of injectable combinations either as the first injectable in people with HbA~1c~ \> 10.0% (\> 86 mmol/mol) and/or 2.0% (22 mmol/mol) above target, or if people with T2D are not reaching HbA~1c~ targets on monotherapy. The DUAL clinical trial program demonstrated the efficacy and safety of IDegLira not only compared with GLP-1RA monotherapy but also compared with basal insulin and basal--bolus therapy regardless of prior insulin therapy. In a real-world setting, the EXTRA study also found that people treated with IDegLira for 6 months experienced improvements in clinical endpoints compared with the beginning of the study. While there was a lower reduction in HbA~1c~ than recorded in the DUAL program, this may be due to the treatment regimen not being followed as rigorously in a real-world setting, as has been demonstrated previously \[[@CR95]\].

We recommend that FRCs, such as IDegLira, are considered as a first injectable therapy for people with T2D, and as a superior alternative to the traditional basal--bolus approach for optimizing glycemic control in individuals not reaching their targets on basal insulin. IDegLira should be initiated at 10 units/dose steps unless the individual is already taking insulin, in which case 16 units/dose steps is recommended. The dose should then be titrated by 2 units/dose steps twice weekly until the individual reaches his or her glycemic target.

Overall, the benefits of consistently improved glycemic control, fewer GI adverse events (than GLP-1RA monotherapy), a lower incidence of hypoglycemia and body weight loss or neutrality (compared with body weight gain seen with insulin), combined with a simple treatment regimen and a durable effect, indicate that IDegLira may help overcome therapeutic inertia and improve medication adherence in people with T2D, thereby leading to better long-term diabetes control. The evidence suggests that IDegLira may provide a more suitable treatment option than insulin alone for individuals at increased risk of hypoglycemia, or concerned about the body weight gain associated with an insulin (basal or basal--bolus) regimen.
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